Compare Shell PLC (SHEL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs Vertex Pharmaceuticals Incorporated — how do they compare? Shell PLC trades at $100.84 (market cap $284.34B), while Vertex Pharmaceuticals Incorporated trades at $508 (market cap $127.55B). The key difference: Shell PLC is far larger — about 2.2× Vertex Pharmaceuticals Incorporated's market cap, and Shell PLC pays a 3.12% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Shell PLC for 90 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SHEL | VRTX | |
|---|---|---|
Market Cap | $284.34B | $127.55B |
Volume | 9,097,469 | 1,487,944 |
Sector | Energy | Health |
52-Week High | $100.20 | $557.96 |
52-Week Low | $70.31 | $407.37 |
Typical Hold Time | 90 Days | 120 Days |
Enterprise Value | $326.04B | $121.68B |
Dividend Yield | 3.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $96.85, down 0.79% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company's valuation ratios are attractive, with a P/E of 11.08 and P/S of 0.97, while profitability metrics like a 14.35% ROE and 8.76% net margin reflect solid fundamentals. Recent news highlights strategic expansions in LNG capacity and carbon capture projects, positioning Shell for long-term growth in energy transition markets.
The outlook for SHEL is positive, supported by analyst consensus favoring Buy ratings and a $102.53 price target. Key opportunities include LNG expansion and portfolio optimization, but risks involve volatile oil prices and execution challenges in new projects. The stock offers value with upside potential, though investors should monitor energy market dynamics and debt levels.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
